secwatch / observer
8-K filed December 5, 2025, 6:59 PM ET ticker NTHI CIK 0001979414
other material confidence high sentiment positive materiality 0.65

NeOnc raises $1M from Saad Naja; AI study shows ultrasound boosts NEO100 against brain tumors

NEONC TECHNOLOGIES HOLDINGS, INC.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

NEONC TECHNOLOGIES HOLDINGS, INC. issued 111,732 shares of common stock to Saad Naja for $8.95 per share.

Security
common stock
Shares
111,732 shares
Purchaser
Saad Naja
Consideration
$8.95 per share
Exact text from the filing
issue and sell 111,732 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”). The per share purchase price of the Shares is $8.95, which represents the closing price of the Common Stock as reported on the Nasdaq Capital Market on November 28, 2025. The Shares were sold for approximately $1 million. The
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEONC TECHNOLOGIES HOLDINGS, INC. entered into Securities Purchase Agreement with Saad Naja valued at approximately $1 million (effective 2025-12-01).

Action
entry
Agreement
equity purchase
Counterparty
Saad Naja
Value
approximately $1 million
Effective
2025-12-01
Exact text from the filing
On December 1, 2025, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with Saad Naja (the “Investor”) to issue and sell 111,732 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”).
View on SEC.gov

25 equity issuances filed in the last 30 days. Browse all equity issuances →

NEONC TECHNOLOGIES HOLDINGS, INC. filing history →

Source: SEC EDGAR
accession 0001829126-25-009754
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.